Production (Stage)
Silence Therapeutics plc
SLNCF
$1.59
$0.6263.92%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -68.72% | 12.33% | -43.35% | 0.15% | 16.70% |
| Total Depreciation and Amortization | -1.87% | -1.30% | -6.57% | -1.47% | -1.16% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -65.31% | -92.87% | -14.94% | -48.87% | -26.12% |
| Change in Net Operating Assets | 82.78% | -60.69% | 106.96% | 124.99% | -75.99% |
| Cash from Operations | -47.63% | -40.66% | -10.64% | 34.64% | -4.26% |
| Capital Expenditure | -914.42% | -294.29% | -156.57% | -25.06% | 89.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 39.36% | -225.55% | -7,668.30% | 3.37% | -62.06% |
| Cash from Investing | 38.69% | -227.01% | -8,079.57% | 3.27% | -60.44% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -56.14% | 2.51% | 110.00% | 111.94% | 143.93% |
| Issuance of Common Stock | -95.45% | 409.35% | 839.16% | 240.38% | 270.61% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 4,370.56% | 4,370.56% | 179.75% | -- | -- |
| Cash from Financing | -93.78% | 350.85% | 700.16% | 195.57% | 224.60% |
| Foreign Exchange rate Adjustments | -95.96% | -126.55% | -2.57% | 194.00% | 325.62% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -192.26% | 1,492.80% | 114.05% | 481.44% | 656.93% |